Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
08 February 2019Website:
http://www.gossamerbio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 23:58:46 GMTDividend
Analysts recommendations
Institutional Ownership
GOSS Latest News
Oppenheimer initiated coverage on Gossamer Bio Inc GOSS, a clinical-stage biopharmaceutical company, with an Outperform rating and a price target of $9.
Gossamer Bio announced a partnership with Chiesi Group to develop and market its drug seralutinib for various conditions related to blood pressure.
Gossamer Bio, Inc. (GOSS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, GOSS's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross.
Gossamer Bio (NASDAQ: GOSS ) just reported results for the fourth quarter of 2023. Gossamer Bio reported earnings per share of -21 cents.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that it will host a public conference call and webcast for investors and analysts on Monday, December 18, 2023 at 8:30 am ET to discuss the latest seralutinib clinical data from the ongoing TORREY Phase 2 Open-Label Extension Study in PAH patients. Sera.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Profes.
Shares of Gossamer Bio fell Thursday, and the company earned a downgrade from analysts at UBS. Citing a "lack of near-term catalysts," the firm downgraded the biopharmaceutical company to Neutral from Buy and slashed its price target to $1.25 from $8.
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT. Gossamer's management team will be joined by world-renowned PAH key opinion leaders, Dr. Ray Benza, Dr. Ardi Ghofrani, and Dr. Jim White to discuss the upcoming P.
Merck's Sotatercept showed significant improvements in PAH patients in Phase 3 STELLAR trial with a primary endpoint of improvements in pulmonary vascular resistance, 6-minute walk distance, and NT-proBNP levels. Gossamer Bio's seralutinib showed clear efficacy in the Phase 2 TORREY trial, albeit not meeting expectations, and is moving forward with a revised Phase 3 trial.
What type of business is Gossamer Bio?
Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company. The company was registered in the state of Delaware on October 25, 2015, and is based in San Diego, California. They have 4 product candidates in clinical stage and several preclinical programs: GB001 (DP2 antagonist) - for the treatment of eosinophilic asthma and other allergic reactions. GB002 (PDGF receptor kinase inhibitor) - for the treatment of pulmonary arterial hypertension. GB004 (HIF-1 α stabilizer) - for the treatment of inflammatory bowel disease, including ulcerative colitis, Crohn's disease. GB1275 (CD11b modulator) - for the treatment of oncological diseases. None of their developed drugs have reached the commercial stage. All are in various stages of preclinical development.
What sector is Gossamer Bio in?
Gossamer Bio is in the Healthcare sector
What industry is Gossamer Bio in?
Gossamer Bio is in the Biotechnology industry
What country is Gossamer Bio from?
Gossamer Bio is headquartered in United States
When did Gossamer Bio go public?
Gossamer Bio initial public offering (IPO) was on 08 February 2019
What is Gossamer Bio website?
https://www.gossamerbio.com
Is Gossamer Bio in the S&P 500?
No, Gossamer Bio is not included in the S&P 500 index
Is Gossamer Bio in the NASDAQ 100?
No, Gossamer Bio is not included in the NASDAQ 100 index
Is Gossamer Bio in the Dow Jones?
No, Gossamer Bio is not included in the Dow Jones index
When does Gossamer Bio report earnings?
The next expected earnings date for Gossamer Bio is 08 August 2024